Regen-D

Quick links to important sections

Regen-D

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Regen-D

What is Regen-D? Overview and Quick Facts

Property Description
Active ingredient Nepidermin (Recombinant Human Epidermal Growth Factor)
Form Gel or Ointment
Pharmacological class Growth Factor (Dermatological)
General purpose Stimulates skin regeneration and tissue repair
Origin Biopharmaceutical (Recombinant technology)

What is Regen-D and Its Pharmacological Class?

Regen-D is a specialized biopharmaceutical agent formulated for topical application whose primary therapeutic role is to stimulate tissue repair. Its active ingredient is the substance Nepidermin, which is scientifically classified as Recombinant Human Epidermal Growth Factor (rhEGF).

As a member of the pharmacological class of growth factors, Regen-D functions by mimicking the natural proteins the body produces to signal cell growth and multiplication. Specifically, it is designed to target the skin's regenerative processes, assisting in the healing of wounds by promoting the formation of new epithelial cells and granulation tissue.

What side effects are possible with Regen-D?

Possible Side Effects and Safety Information

The safety profile of Regen-D (Nepidermin) is characterized by adverse reactions that are primarily localized to the site of application. According to official regulatory documentation, these reactions are observed infrequently and do not typically involve systemic effects.


Documented Adverse Reactions

Adverse reactions associated with this topical recombinant growth factor are officially classified by frequency as occurring in very few cases.

Adverse Reaction Category Officially Documented Effects
System-Organ Class Skin and Subcutaneous Tissue Disorders (Application site reactions)
Local Reactions Pain, rash, and skin irritation at the site of application
Serious Reactions No serious adverse reactions have been reported in the clinical trials cited in the regulatory documents.

Safety Restrictions and Contraindications

The medicine is subject to explicit regulatory safety restrictions regarding its use in specific patient populations and conditions. These restrictions define the formal boundaries for when the product should not be used.

  • Population-Specific Exclusion: Regen-D is formally contraindicated for use in pregnant women and lactating women.
  • Immune Status: It is contraindicated in individuals who are immune-compromised or receiving immunosuppressive or immune-stimulant therapy.
  • Product Components: Use is forbidden in cases of known hypersensitivity to Nepidermin or any other component of the formulation.
  • Drug-Class Restriction: The label carries a restriction prohibiting its concurrent use with any other growth factor containing gel, cream, or drug.

Overdose and Emergency Response

Overdose and when to seek help

Official Overdose Profile (Regen-D)

Official regulatory documents characterize the overdose profile for the topical application of Nepidermin (Regen-D). Application of quantities exceeding the amount required is not likely to cause severe symptoms, which is a classification based on the intended route of administration. However, the regulatory guidance focuses heavily on the risk associated with exposure by the non-intended route: accidental ingestion of the gel or ointment formulation. In such cases, there is potential for harm, and the situation triggers explicit, mandated emergency actions.


Emergency Action and When to Seek Help

Due to the identified risk of harm from accidental oral exposure, the official emergency-response statements are clear. Immediate medical intervention may be required if the product is swallowed. The guidance mandates that individuals must seek immediate medical help if accidental ingestion occurs or if any unexpected or undesirable effects are experienced following the use of an excessive amount. No specific antidote is mentioned in the regulatory documents, and no procedural instructions, such as gastric lavage, are formally documented within the overdose section of the official labeling. Furthermore, the regulatory information does not document population-specific overdose notes for groups such as the elderly or those with underlying conditions.

Therapeutic Uses of Regen-D

Therapeutic Purpose of Regen-D

Regen-D is a topical preparation containing recombinant human epidermal growth factor (rhEGF). Its primary function is to accelerate the natural healing process of the skin by stimulating cell proliferation and migration. By mimicking the body's endogenous growth factors, it assists in the formation of new tissue and the closure of wounds that may otherwise be slow to heal.

Main Clinical Uses

Diabetic Foot Ulcers

The most common application for Regen-D is the management of neuropathic diabetic foot ulcers. In patients with diabetes, the natural wound healing cycle is often impaired due to poor circulation and reduced growth factor activity. The application of rhEGF helps to restart the healing process, encouraging the development of granulation tissue and reducing the time required for complete ulcer closure.

Chronic Pressure Sores

Regen-D is utilized in the treatment of pressure ulcers (bedsores) that have reached a stage where the skin has broken down and exposed underlying tissue. It supports the repair of damaged dermal layers in patients who are immobilized or have limited mobility.

Skin Grafts and Donor Sites

In surgical contexts involving skin grafts, Regen-D is used to facilitate faster recovery at the donor site—the area from which healthy skin was removed. It also assists in the integration and stabilization of the graft at the recipient site by promoting rapid epithelialization.

Burn Management

For partial-thickness burns (second-degree burns), Regen-D helps in restoring the skin barrier. By stimulating the keratinocytes and fibroblasts, it aids in reducing the duration of the healing phase and may contribute to improved aesthetic outcomes in the healed tissue.

Benefits of rhEGF Therapy

  • Acceleration of Re-epithelialization: The primary benefit is the speed at which new skin cells cover a wound, reducing the window of time the internal tissues are exposed.
  • Tissue Quality: By promoting a more organized cellular response, the treatment can lead to better structural integrity of the newly formed skin.
  • Management of Non-Healing Wounds: It provides a therapeutic option for chronic wounds that have failed to respond to standard wound care protocols.

Regulatory References

  1. Product Information for REGEN-D®150 - NAFDAC

Eligibility and Restrictions for Use

Regen-D (recombinant human epidermal growth factor, or rhEGF) is a topical gel indicated for the promotion of wound healing. Its use is generally recommended for patients with specific types of wounds to accelerate tissue repair and regeneration.

Indications for Use

Regen-D is typically prescribed for the management of the following conditions:

  • Chronic Ulcers: Including diabetic foot ulcers, chronic leg ulcers, and bedsores (pressure ulcers).
  • Burns: First- and second-degree burns.
  • Skin Grafts: To promote healing at donor sites.

Contraindications (When Not to Use)

The use of Regen-D is not recommended in several specific circumstances to prevent adverse effects or complications. Do not use this product if any of the following apply:

Condition Reason for Contraindication
Hypersensitivity Known allergy to recombinant human epidermal growth factor or any other ingredient in the gel.
Immune Status Individuals who are immunocompromised or are receiving immune-suppressant or immune-stimulant therapies.
Pregnancy/Lactation Pregnant or breastfeeding women.
Concurrent Therapy Simultaneous use with other medications or products containing a growth factor.

Patients should always discuss their full medical history, including all current medications and supplements, with a healthcare provider before starting treatment with Regen-D.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

Regen-D (recombinant human Epidermal Growth Factor or rhEGF) is formulated for topical use, resulting in minimal to no systemic absorption of the active ingredient. Consequently, the product's official interaction profile, based on regulatory labeling, is primarily focused on local pharmacodynamic incompatibilities and systemic patient status restrictions.


Documented Interaction Restrictions

Classification Interacting Agents / Conditions Practical Regulatory Constraint
Prohibited Combinations (Topical) Other growth factor-containing gels or creams Must not be used concurrently or co-administered on the same area.
Contraindicated Status (Systemic) Immunosuppressive or immune-stimulant therapy Use of Regen-D is contraindicated in patients receiving these systemic treatments.
Population-Specific Constraint Immune-compromised individuals Contraindication for use applies to this specific patient population.

Absence of Systemic Pharmacokinetic Interactions

No clinically significant pharmacokinetic interactions (e.g., involving CYP450 enzymes or drug transporters) are documented in the regulatory information. This absence is consistent with the drug's topical administration route and the reported lack of significant systemic absorption. Furthermore, no interactions with food, alcohol, or common supplements are established or documented in the official labeling.

Mechanism of Action

Regen-D's mechanism of action begins at the molecular level by targeting the receptor activator of nuclear factor kappa-B ligand (RANKL) signaling cascade. The compound functions as a specific antagonist, engaging directly with the RANKL receptor located on the surface of osteoclast precursor cells. This binding event competitively blocks RANKL from activating its receptor. This antagonistic interaction interrupts the downstream intracellular cascade required for osteoclastogenesis, specifically inhibiting the differentiation and maturation of osteoclast precursors into bone-resorbing osteoclasts. Consequently, the population and activity of mature osteoclasts are reduced. This reduction leads to a decrease in osteoclast-mediated resorption of the bone matrix. The overall effect is a modulation of the bone remodeling cycle, shifting the balance of signaling in favor of bone formation relative to resorption, thus influencing skeletal microarchitecture.

Dosage and Administration Information

How to Use Regen-D

Regen-D (Nepidermin) is strictly intended for topical application to the affected area of the skin, delivered as a gel formulated in strengths of 60 mu g/g or 150 mu g/g. The administration schedule requires the gel to be applied twice daily, maintaining a separation of approximately 12 hours between applications.


Dosing and Preparation Protocol

The dosage is not fixed by mass but is determined by the size of the wound. The regimen requires applying a thin, even layer of the gel sufficient to fully cover the entire ulcer or wound surface. This must be done following a strict preparation procedure: immediately before each application, the wound and surrounding skin must first be cleansed using water or saline, and then gently patted dry with sterile material to ensure proper administration conditions.


Application Method and Course Duration

To prevent contamination, the gel must be applied using a sterile cotton swab or similar aid, and direct contact between the tube opening and the wound surface must be avoided. The treatment course continues until the wound achieves complete closure. The recommended protocol permits the application to be continued for an additional 2 to 3 weeks after initial healing, though the total therapy duration for complex wounds may extend up to 15 to 20 weeks.


Special Constraints on Use

Prescribing information imposes specific procedural constraints: the product is restricted to use by a single patient, and it must not be co-administered with any other growth factor-containing topical preparation. Furthermore, its use is advised against or avoided in specific populations, including pregnant or lactating women.

These instructions establish a standardized, procedural framework for the administration of the medication, defining the route, frequency, and preparation steps necessary for its prescribed use.

Recent Clinical Evidence

Regen-D: Recent Clinical Evidence

Regen-D is a formulation containing recombinant human Epidermal Growth Factor (rhEGF), a protein studied for its potential role in promoting the formation of granulation tissue and re-epithelialization in wounds. Research on this formulation has primarily focused on its use as an adjunctive treatment for diabetic foot ulcers (DFUs), in conjunction with standard wound care.


Summary of Clinical Findings

Clinical trials, including randomized controlled studies and post-marketing surveillance, have investigated the outcomes associated with the topical application of rhEGF. The evidence suggests that, when compared to standard care alone, the addition of rhEGF may increase the incidence of complete ulcer closure and reduce the estimated time to wound healing in certain patient populations with DFUs.

  • One randomized, controlled trial observed that a greater percentage of subjects treated with rhEGF achieved complete ulcer healing compared to the control group (78% versus 52%), and the median time to closure was shorter in the treatment group.
  • Integrated analyses of early trials, which assessed the effect of the product, have similarly noted a statistically significant increase in the incidence of complete healing when compared against a vehicle control or standard care.

Current Practice Guidelines

It is important to note that the use of growth factors, including those found in Regen-D, has been the subject of review by international clinical guidelines. Some authoritative guidelines, such as those from the International Working Group on the Diabetic Foot (IWGDF), suggest that growth factors should not be considered a routine adjunct to standard care for DFU wound healing due to concerns about the overall consistency and quality of evidence, as well as cost-effectiveness data. Therefore, the decision to use this therapy is typically reserved for specialized clinical settings and is made on a case-by-case basis by healthcare providers.

Frequently Asked Questions (FAQ)

Common questions about Regen-D (FAQ)


Q: How quickly should I expect to see an effect after starting Regen-D?

A: According to official clinical data, Regen-D is designed to promote the formation of new tissue and accelerate healing. Clinical data on chronic wounds, such as diabetic foot ulcers, indicates that the product may help reduce the time needed for complete wound closure. Reported closure times in studies generally vary, with some trials observing closure within approximately 4 to 9 weeks.

Q: For how long is Regen-D typically applied or used in a treatment course?

A: Official product information states that treatment continues until the wound has achieved complete closure. The total duration depends on the wound type, with complex wounds sometimes requiring up to 15 to 20 weeks of therapy. In some cases, application may be continued for an extra 2 to 3 weeks after initial healing.

Q: Are there any common over-the-counter medicines that shouldn't be taken with Regen-D?

A: The most important restriction is that Regen-D must not be used on the same area concurrently with any other topical product containing a growth factor. Because the medicine is applied to the skin with minimal absorption into the bloodstream, official regulatory documents do not list specific systemic or pharmacokinetic interactions with common over-the-counter medicines.

Q: Is it normal to feel a mild stinging sensation when first applying Regen-D?

A: Yes, localized pain, which can be experienced as a mild stinging or burning sensation, is listed in the official documentation as one of the documented, though infrequent, adverse reactions at the application site. If any skin irritation or pain occurs or persists, it should be brought to the attention of a healthcare provider.

Q: What if I forget to apply a dose of Regen-D – should I apply it late or wait?

A: Official guidance suggests maintaining the regular application schedule if a dose is missed, and that doses should not be doubled. It is advised to follow the specific instructions provided by the prescribing physician.

Q: How is Regen-D packaged and what are the standard available sizes?

A: Regen-D is typically presented as a gel in a tube format, often available in sizes such as 7.5g or 15g. The official product insert emphasizes that the contents of a single tube should be used for one individual patient only to help prevent contamination.

Q: What are the potential long-term effects of using Regen-D for many weeks?

A: Clinical trials have assessed the product's safety for use over several months, with treatment periods extending up to 20 weeks. During these studies, adverse reactions remained predominantly localized to the skin and were infrequent, with no serious systemic adverse events reported.

Q: Is Regen-D considered an antibiotic or a different type of medicine?

A: Regen-D is classified as a biopharmaceutical agent and belongs to a class of medicines called growth factors. Its active ingredient, Nepidermin (rhEGF), is a protein that stimulates tissue repair. It is not an antibiotic medicine.

Q: What is the science behind how Regen-D helps with healing?

A: Its mechanism involves the active ingredient, Nepidermin, binding to receptors on skin cells. This action is understood to promote natural healing processes, such as the growth and repair of new skin cells (re-epithelialization).

Q: Does Regen-D help with scar reduction, or is it only for initial wound healing?

A: Regen-D is primarily indicated for promoting initial wound healing, re-epithelialization (the formation of new skin), and the reduction of healing time. Clinical information for its use in burns and skin grafts suggests its regenerative action aims to lead to better-quality healing, which is often associated with minimal scarring.

Q: Can Regen-D be used on burns, or is it only for cuts and abrasions?

A: According to official product indications, Regen-D is prescribed for the management of various wounds, including chronic ulcers, skin grafts, and specifically for first- and second-degree burns, in addition to simpler cuts and abrasions.

Q: Is Regen-D safe to use on children or is it generally for adults only?

A: The product is primarily intended for use in adults. Official regulatory information often advises caution or consultation with a healthcare provider before using the gel on individuals under 18 years of age, as safety data for the pediatric population may be limited.

Q: What should I do if I accidentally apply too much Regen-D?

A: Official guidance recommends rinsing the area with water if an excessive amount is applied. A healthcare provider should be informed if any symptoms of discomfort, such as persistent irritation or redness, occur or worsen.

Q: Are there any known issues with using Regen-D if you have sensitive skin?

A: Individuals who have a known hypersensitivity or allergy to the active ingredient (Nepidermin) or any other component in the gel are strictly contraindicated from using the product. Local reactions, including skin irritation, are the most common documented side effects.

Q: Can Regen-D be used simultaneously with a simple bandage or dressing?

A: Yes, official application instructions indicate that the area where Regen-D has been applied can be covered with a sterile dressing or simple bandage after the gel has been allowed to dry.

Q: Why do some people say Regen-D speeds up their recovery time?

A: The active ingredient in Regen-D is a growth factor that directly stimulates the body's natural healing pathways. Clinical data supports that, by accelerating cellular processes like re-epithelialization, the product may lead to significantly shorter healing times for chronic wounds compared to standard care alone.

Q: Does Regen-D need to be stored in the refrigerator or at room temperature?

A: According to official regulatory instructions, the product should be stored at room temperature, typically defined as below 25 C or 30 C. It is explicitly stated that the gel must be kept away from direct heat and light, and it must not be frozen.

Q: Does the time of day I apply Regen-D matter for its effectiveness?

A: The official dosing protocol requires the gel to be applied twice daily, with a separation of approximately 12 hours between each application. This emphasizes the importance of a consistent twice-daily schedule rather than requiring application at specific morning or evening hours.

Q: Are there any specific cleaning products or soaps that will interfere with Regen-D?

A: The official protocol for applying the gel specifies that the wound and surrounding skin must be cleansed with only water or saline immediately before each application. Use of only these simple cleaning agents is recommended to ensure proper conditions for the medication to work.

Q: Is there any component of Regen-D that is derived from animal or plant sources?

A: The active ingredient is recombinant human Epidermal Growth Factor (rhEGF) or Nepidermin, which is produced using biotechnology. This method ensures the active ingredient is not derived from animal or plant sources.

Q: What is the difference between Regen-D gel and Regen-D cream, if both exist?

A: The product is manufactured and regulated as a gel formulation. Official regulatory information does not describe a cream formulation of Regen-D.

Q: Why is Regen-D often mentioned in discussions about tissue repair?

A: Regen-D is a highly specialized biopharmaceutical agent whose primary therapeutic role is to stimulate tissue repair. Its active ingredient is a growth factor that directly targets cellular pathways to promote skin regeneration and healing, making it a key topic in discussions about advanced wound management.

Q: Can Regen-D be used on internal wounds or mucous membranes?

A: Official instructions specify that Regen-D is intended only for external, topical application to the affected area of the skin. It is not for internal use or use on mucous membranes.

Q: How does the concentration of the active ingredient affect the strength of Regen-D?

A: Regen-D is available in different concentrations of the active ingredient, such as 60 mu g/g and 150 mu g/g. The specific strength that is appropriate for a patient's wound type or severity is determined and prescribed by a healthcare professional.

Q: Does the application technique for Regen-D influence its results?

A: Official instructions detail a specific application technique, including cleaning the wound and using a sterile swab. These steps are advised to maintain sterility and create optimal conditions for the product to function effectively.

Q: Is it common for Regen-D to cause temporary discoloration of the skin?

A: Skin discoloration at the application site is listed as one of the documented, though infrequent, adverse reactions associated with the use of the gel in official patient information.

How should Regen-D be stored and disposed of?

How to Store and Dispose of Regen-D?

Official regulatory guidelines define specific conditions for storing and discarding Regen-D to maintain the product's stability and integrity.

Storage and Handling Requirements

Requirement Type Official Regulatory Statement
Temperature Store at Room Temperature (typically 10 C to 25 C or below 30 C).
Prohibited Conditions Do not freeze. Avoid direct exposure to heat, light, and moisture.
Child Safety Keep out of the sight and reach of children.
Product Integrity Must be kept in the original container. A single tube should be used for individual patient to prevent contamination.

Disposal Instructions

To dispose of unused or expired Regen-D, the product and any associated waste material must be discarded in accordance with local requirements for pharmaceutical waste. Using the product after the expiration date listed on the carton is prohibited by regulatory labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Regen-D found in:

A-Z Index: